Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Lenalidomide 8Dexamethasone 6Calcium Dobesilate 6Melphalan 3elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Peripheral Blood Stem Cell Transplantation 2Bortezomib 2pomalidomide 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1Watchful Waiting 1Urination 1Transplantation, Autologous 1Stem Cell Transplantation 1Receptors, Interleukin-6 1Observation 1Nivolumab 1Metformin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1IPH-2101 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Smoldering Multiple Myeloma × Urination × Clear all
NCT03951220 2025-08-19

LOOMIS

Oxford University Hospitals NHS Trust

Completed
67 enrolled 24 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡